Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
Zacks News
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).
Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?
by Zacks Equity Research
Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why
by Zacks Equity Research
Let us look at the factors that have led to the increase in share price of Emergent (EBS).
Why Is Emergent Biosolutions (EBS) Up 8% Since Its Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inovio's Influenza Vaccine Shows Potential, Shares Rally
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.
Exact Sciences (EXAS) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
The shares of Exact Sciences (EXAS) rose over 5% yesterday.
Illumina (ILMN) Looks Good: Stock Adds 6.9% in Session
by Zacks Equity Research
Illumina (ILMN) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
Emergent Starts Phase II Study on Anti-influenza Candidate
by Zacks Equity Research
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
5 Reasons to Pick Emergent as an Investment-Worthy Stock
by Zacks Equity Research
Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.
New Strong Buy Stocks for January 2nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
2 Biotech Stocks with Month-Long Upward Estimate Revisions
by Zacks Equity Research
Although the biotech sector initially picked up this year, it witnesses a correction since October. However, it is a good idea to select stocks witnessing positive estimate revisions for a month now.
Should You Get Rid of Peregrine Pharmaceuticals (PPHM) Now?
by Zacks Equity Research
Peregrine Pharmaceuticals (PPHM) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and year.
Five Marvelous Momentum Stocks to Buy Now
by David Bartosiak
These five Zacks Rank #1 (Strong Buy) stocks are surging on huge demand and breaking higher
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.
What's in Store for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.
Agios Pharmaceuticals (AGIO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Agios' (AGIO) only marketed drug Idhifa that looks effective to cure patients with relapsed or refractory acute myeloid leukemia might drive the company's earnings in Q3.
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.
Emergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
CVS Health (CVS) Releases Encouraging Flu Shot Survey Data
by Zacks Equity Research
CVS Health's (CVS) survey on flu vaccination came up with positive outcome. The data confirms untapped opportunities in the flu vaccine market.